# Mazdutide > A glucagon / GLP-1 dual agonist (oxyntomodulin-based) approved in China for weight management and diabetes — not yet FDA-approved. - Also known as: IBI362, LY3305677 - Class: Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/mazdutide ## Overview Mazdutide is a once-weekly glucagon / GLP-1 dual receptor agonist based on mammalian oxyntomodulin, the natural gut hormone that activates both receptors. Licensed by Innovent Biologics from Eli Lilly for China, it became the first GCG/GLP-1 dual agonist to reach the market when China’s NMPA approved it in 2025 — first for chronic weight management, then for type 2 diabetes. It is not FDA-approved; Eli Lilly retains rights outside China, where it remains investigational. Mazdutide is built on oxyntomodulin, a naturally occurring gut hormone that — unusually — activates both the GLP-1 and glucagon receptors on its own. Engineering that dual activity into a stabilized, acylated, once-weekly peptide gives mazdutide the same glucagon/GLP-1 profile as survodutide, reached from a different molecular starting point. Its development is notable for geography. Eli Lilly created the molecule (LY3305677) and licensed Chinese rights to Innovent Biologics (as IBI362) in 2019. In 2025 China’s NMPA approved it — first for long-term weight management, then for glycemic control in type 2 diabetes — making it the first glucagon/GLP-1 dual agonist approved anywhere. Late-stage Chinese trials (the GLORY program) reported weight reductions around 20% at higher doses. It is not FDA-approved, and outside China it remains investigational. ## Mechanism Dual agonism at the glucagon and GLP-1 receptors, modeled on oxyntomodulin — combining GLP-1 satiety and insulin effects with glucagon-driven energy expenditure. ## Chemistry | Property | Value | | --- | --- | | Molecular formula | C207H317N45O65 | | Molecular weight | 4476 Da | | CAS number | 2259884-03-0 | | PubChem CID | [167312357](https://pubchem.ncbi.nlm.nih.gov/compound/167312357) | ## Research areas Studied in: Obesity, Type 2 diabetes, MASH. Guides on this site: - [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss. ## Key research - Oxyntomodulin-based dual agonism — activates both glucagon and GLP-1 receptors, modeled on the natural dual-acting gut hormone. - First-in-class approval (China) — China’s NMPA approved it in 2025 for weight management and then type 2 diabetes; the first GCG/GLP-1 dual agonist to market. - Weight reduction — late-stage Chinese trials (GLORY) reported ~20% mean weight loss at higher doses. - Developed by Lilly / Innovent — Innovent holds Chinese rights; Lilly retains rights elsewhere. - Not FDA-approved — approved in China only; investigational elsewhere. ## Storage, handling & synthesis **Synthesis.** An oxyntomodulin-based glucagon/GLP-1 dual agonist, acylated for once-weekly dosing and stabilized with unnatural residues, made by solid-phase synthesis. As with the other long acylated incretins, the fatty-acid step and deletion-sequence control over a long backbone define the quality picture. ## FAQs ### What is mazdutide? Mazdutide is a once-weekly glucagon / GLP-1 dual receptor agonist based on oxyntomodulin, approved in China for weight management and type 2 diabetes and developed by Eli Lilly and Innovent. ### Is mazdutide FDA-approved? No. It was approved in China (2025) for weight management and diabetes, but it is not FDA-approved; outside China it remains investigational. This page is a research and educational reference. ### How is it different from survodutide? Both are glucagon / GLP-1 dual agonists, but mazdutide is based on the natural dual-acting hormone oxyntomodulin, while survodutide is a separate engineered peptide; they come from different developers. ### What does the glucagon component add? Glucagon-receptor activation is studied for increasing energy expenditure and reducing liver fat, complementing GLP-1’s appetite and glucose effects. ## Latest research Recent trials and publications mentioning Mazdutide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer](https://clinicaltrials.gov/study/NCT07781150) — NOT_YET_RECRUITING · PHASE2 · NCT07781150 - [QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy](https://clinicaltrials.gov/study/NCT07775846) — NOT_YET_RECRUITING · PHASE4 · NCT07775846 - [Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial](https://clinicaltrials.gov/study/NCT07767552) — NOT_YET_RECRUITING · NA · NCT07767552 - [A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight](https://clinicaltrials.gov/study/NCT06143956) — RECRUITING · PHASE2 · NCT06143956 - [Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)](https://clinicaltrials.gov/study/NCT07718126) — NOT_YET_RECRUITING · PHASE2, PHASE3 · NCT07718126 - [Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide](https://clinicaltrials.gov/study/NCT07713992) — NOT_YET_RECRUITING · NA · NCT07713992 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/mazdutide Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.